Comprehensive Early Global Strategic Development and Commercialization from Phase 2-Launch and Lifecycle Planning focused on:Market AssessmentsUnderstanding Customer Needs and Competitive OfferingsCustomer SegmentationProduct Target Profile DevelopmentProduct Positioning StrategiesWillingness to Pay and Pricing ModelsMarket Entry Strategies (Organic and Inorganic)Life Cycle ManagementLong-Term Disease Area StrategiesSpecialize in highly matrixed pharmaceutical organizations requiring expertise in successful large molecule development, commercialization and life cycle globally aligned strategies

Led a highly matrixed cross functional team consisting of Drug Development, Regulatory, Operating Companies, Global Strategic Marketing, Health Economics and Pricing, Medical Affairs, Market Research and Global Strategic Analytics in order to develop and execute the commercialization and lifecycle strategy for STELARA, J&J’s first global immunology product as well as a new compound guselkumab. Currently working on Disease Area Stronghold for psoriasis and Pulmonolgy.Partner with all regions to incorporate marketing excellence into all aspects of the global and regional commercial strategy, provide commercial leadership and guidance to the global regulatory and clinical development plans for the early and late stage life cycle management of the compound and champion the commercial strategy.• Led the development and launch commercialization of STELARA resulting in $1.5B of global sales in 2014, exceeding all forecasts with particular emphasis in US, EMEA and Asia Pacific in Psoriasis• STELARA achieved #1 product launch ranking from IMS in 2009• Developed global growth acceleration opportunities/initiatives to exceed BP forecasts in US and EMEA• Achieved full funding from GOC for 6 new lifecycle indications ( PsA, Crohn’s Disease, Sarcoidosis, Ulcerative Colitis, Ankylosingspondelitis and Primary Biliary Cirrhosis)• Achieved full funding for a guselkumab compound in both Rheumatoid Arthritis and Psoriasis

Led sales strategy, direction and tactical execution for a high growth biological product, targeting Rheumatology Therapeutic area. Organization included a team of 250+ specialty sales representatives, 24 area business managers, 6 regional training managers and 6 regional business directors to achieve $1.2 Billion in sales in 2004. Launched three new indications in two new disease categories to over 3,500 physicians and allied health personnel in community and academic markets.• Achieved net sales growth of over 20.27% in 2004 vs.2003 fiscal period, with significant contribution to total Johnson and Johnson biopharmaceutical growth. Achieved 103% of sales objective. Managed budget of 50 MM in direct T&E, A&P and operational expenses. • REMICADE® achieved $1 Billion net sales in seven months, the top producing franchise in the history of Centocor. Exceeded sales, market penetration and patient share YTD.• Exceeded all company objectives achieving focus and flawless execution during major launches, Medicare reform, co-promotions and change in business practices. Created new sales incentive structures and retained all but 2% of the top 25% of the sales organization YTD. Turnover rate of all employees is less than 6%.• Analyzed and established field force structure, management, size, territory alignment, account focus to support emerging business requirements; restructured field sales organization.• Executed 2004 sales strategy with 5 new regional business directors out of 6 due to optimization.

P&L responsibility for $1 Billion franchise in rheumatology community and hospital markets. Responsible for directing development and execution of positioning, messaging, strategic business planning, forecasting, professional and consumer marketing, visual aids, clinical resources, advisory boards, domestic and international congresses and all other in line initiatives.• Achieved net sales growth of over 32% versus 2002.Managed budget of $52mm in direct marketing and selling expenses.• REMICADE® achieved $1 Billion in net sales in 11 months• Achieved market penetration of 19%, message recall of 95%, and market share of 56% through close alliance and alignment of objectives with sales organization • Led the development and execution of DTC and experimental marketing strategies and tactics for REMICADE® culminating in a paradigm shift toward early intervention to expand class and drive brand use.• Led the launch of strategy development, positioning, message alignment and mega branding with joint partner company at major international conference. • Awarded President’s Club status for contribution to corporate goals.